{"schema_version":"secwatch.filing_event.v1","accession":"0001739104-24-000016","form_type":"8-K","ticker":"ELAN","cik":"0001739104","company_name":"Elanco Animal Health Inc","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.832752+00:00","generated_at":"2026-06-02T11:54:37.020988+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Elanco Q1 revenue $1.205B; adjusted EPS $0.34; FY guidance updated with improved constant currency growth outlook","bullets":["Q1 revenue $1.205B (-4% reported/CC); reported EPS $0.06, adjusted EPS $0.34; adjusted EBITDA $294M (-22%).","FY 2024 guidance: revenue $4.46-4.515B (2-3% CC growth), adjusted EBITDA $960M-$1B, adjusted EPS $0.88-$0.96.","Net leverage 6.1x; expects debt paydown $280-320M in 2024; aqua divestiture closing mid-2024 with proceeds $1.05-1.1B after tax.","Innovation revenue now expected $375-410M in 2024; three pipeline products (Bovaer, Zenrelia, Credelio Quattro) on track for H2 2024 approval.","Kexxtone sales paused due to EU CVMP review; expected ~$20M revenue and ~$18M adjusted EBITDA reduction vs Feb guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0001739104-24-000016","json":"https://secwatch.observer/filing/0001739104-24-000016.json","markdown":"https://secwatch.observer/filing/0001739104-24-000016.md","text":"https://secwatch.observer/filing/0001739104-24-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739104/000173910424000016/0001739104-24-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739104/000173910424000016/elan-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T11:54:37.020988+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"231454e67d80acc64b1098fa5490ee6a88e09e1c","claim":"Elanco Animal Health Inc reported the first quarter of 2024 results: revenue $1,205 million, net income $32 million, EPS $0.06. Guidance reaffirmed.","evidence_excerpt":"Elanco Animal Health Reports First Quarter 2024 Results • First Quarter 2024 Financial Results ◦ Revenue of $1,205 million ◦ Reported Net income of $32 million, Adjusted Net income of $167 million ◦ Adjusted EBITDA of $294 million, or 24.4% of Revenue ◦ Reported EPS of $0.06, Adjusted EPS of $0.34","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739104/000173910424000016/0001739104-24-000016-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2024"},{"label":"Revenue","value":"$1,205 million"},{"label":"Net income","value":"$32 million"},{"label":"EPS","value":"$0.06"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}